Sanibel Captiva Trust Company Inc. Takes Position in Zoetis Inc. (NYSE:ZTS)

Sanibel Captiva Trust Company Inc. acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,424 shares of the company’s stock, valued at approximately $232,000.

Other large investors have also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC lifted its stake in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after buying an additional 4,829,815 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after acquiring an additional 937,700 shares during the period. Marshall Wace LLP lifted its position in Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after acquiring an additional 824,843 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Zoetis by 296.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after acquiring an additional 665,331 shares during the period. Finally, Nordea Investment Management AB grew its position in shares of Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 2.0 %

Shares of ZTS opened at $166.01 on Monday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a 50-day moving average price of $170.93 and a two-hundred day moving average price of $179.98. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm earned $1.36 EPS. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts predict that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.